Need For Blinded Payment In Randomized Trials Is Recognized In Recent Bills
This article was originally published in The Gray Sheet
Executive Summary
Recent legislation is recognizing the need to blind patients and providers to sources of reimbursement in clinical trials to ensure scientifically valid results
You may also be interested in...
Medicare Bill Becomes Law: Industry Focuses On What Didn’t Make the Cut
A Medicare bill made law last week was of interest to device firms as much or more for what it did not contain than for what it did include
CMS Maintains Status Quo On Clinical Trial Coverage, Again
Under intense pressure from Congress, industry and the medical research community, CMS has decided to maintain the status quo for coverage of routine costs in clinical trials
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”